Currently, there are four SGLT-2 inhibitors on the market: Invokana, Farxiga, Jardiance and Steglatro. A lot of trials have been done surrounding this class of medications in regards to both cardiovascular and renal protection. Steglatro is what I would call the late bloomer of the group. It was the last agent to gain FDA approval as well as being last to report on cardiovascular (CV) (heart related) outcomes. Results from the VERTIS CV trial were recently published in October 2020. The VERTIS CV trial demonstrated that ertugliflozin is noninferior for reducing CV events in patients with T2DM and established ASCVD. Like it’s counterparts, Steglatro also demonstrated benefits for heart failure, although this was not tested statistically. On the other hand, no significant benefit was observed for ertugliflozin in regards to renal protection. The benefits on cardiovascular and renal outcomes don’t seem as strong compared to others in the same class. The trial still serves the purpose of confirming the important role of SGLT-2 inhibitors in treating type 2 diabetes patients with comorbid ASCVD.
Cannon CP, Pratley R, Dagogo-Jack S, et al., for the VERTIS CV Investigators. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020;383:1425-35.
Today’s daily piece is written by Taylor Guelda, PCOM SOP PharmD Candidate Class of 2021.
Please share your thoughts and subscribe to receive my blogs.
#SGLT2inhibitor #diabetes #cardiovascular
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.